Oenon Holdings, Inc.
2533・Prime Market・Foods
Business
Oenon Holdings traces its origins to Denbei Kamiya, who founded the company in 1880 (Meiji 13), and centers on Godo Shusei, established in 1924 (Taisho 13), operating as a holding company under a structure adopted in 2003. With 7 consolidated subsidiaries, the group's core business is alcoholic beverages (shochu, chuhai, alcohol, etc.), accounting for 93% of net sales, alongside an enzyme pharmaceuticals business that applies fermentation technology to enzymes, diagnostic reagents, and contract fermentation, and a real estate business involving the leasing and sale of group-owned properties. Major customers include large distribution and food trading companies such as Aeon Topvalu (13.0% of net sales) and Itochu Shokuhin (10.5%). Listed on the Prime Market of the Tokyo Stock Exchange.
Business Model
In the alcoholic beverages business, the company pursues economies of scale by developing private-brand shochu (otsu-rui) and chu-hi products, as well as a packer business, for mass retail distribution channels. In the enzyme pharmaceuticals business, the company leverages the same fermentation infrastructure to achieve a high operating margin of 17.4%, driven by overseas sales of lactase (a lactose-decomposing enzyme) and domestic contract fermentation services (lactic acid bacteria). The real estate business forms the third layer of this structure, generating stable cash flow with a 57.7% operating margin through the leasing of group-owned properties such as the Ginza hotel.
Company Strengths
Fermentation technology cultivated in alcoholic beverage manufacturing has been repurposed for the enzyme pharmaceutical business, achieving an operating margin of 17.4% in food-use enzymes and contract fermentation such as lactase. The difference in profit structure versus the alcoholic beverages business (operating margin of 3.1%) enhances the overall profit stability of the group. Of R&D expenses of ¥591 million, ¥513 million was concentrated in enzyme pharmaceuticals.
The private brand (PB) and packer business in the RTD field, including chuhai, grew at a high rate of 16.2% year on year. Sales to Aeon TOPVALU expanded to ¥11,393 million (13.0% of net sales). Production volume also increased, with chuhai production reaching 91,014 KL (112.5% of the previous period), as deepening transactions with major distributors drive sales growth.
Through fixed-term building lease agreements for "The Royal Park Canvas Ginza Corridor" (total floor area of 7,402.65 sqm), built on the former site of the Oenon Ginza Building, the real estate business achieved an operating margin of 57.7% (operating profit of ¥763 million). Rent revisions contributed to a 26.4% increase in profit year on year.
ENVALITH's Perspective
Performance Trend
Over the past five fiscal years, revenue recovered from a trough of ¥81,120 million in FY2022, and in FY2025 reached a record high with revenue of ¥87,630 million and operating profit of ¥4,136 million. In the first quarter of FY2026 (ending December 2026), the company achieved substantial profit growth, with revenue of ¥21,266 million (up 9.5% year on year), operating profit of ¥1,267 million (up 81.9% year on year), and quarterly profit attributable to owners of the parent of ¥940 million (up 75.2% year on year). The main drivers of profit improvement were reduced manufacturing expenses, improved product mix, and price revision effects in the alcoholic beverages business, along with increased export enzyme sales and contract fermentation in the enzyme pharmaceuticals business. As an external factor, higher raw material costs due to inflation (down ¥60 million) have continued, but this has been absorbed through manufacturing efficiency improvements and price pass-through. The equity ratio improved to 48.8% from 44.2% at the end of the previous fiscal year.
Growth Strategy
Under the Medium-Term Management Plan 2028, the company aims for net sales of ¥93,000 million in 2028 through alcoholic beverage exports, expanded enzyme pharmaceutical production, and DX promotion.
The company aims to capture at-home drinking demand through expanded awareness of the "Tanjaku" (鍛茶) series via TV commercials and social media, the addition of new flavors to "Chuhai Senka" (酎ハイ専科), and the new launch of "Hakata no Hana Sukkiri Mugi Hi no Moto" (博多の華 すっきり麦ハイの素). Chuhai sales in Q1 FY2026 (ending December 2026) grew 13.3% year on year, continuing high growth.
The company is carrying out capital investment to expand production capacity for neutral lactase. Backed by increased orders for domestic fermentation contract manufacturing and strong overseas enzyme sales, the operating margin reached 28.6% in Q1 FY2026 (ending December 2026). The recombinant enzyme product scheduled for launch in FY2027 (Reiwa 9) is being developed as a future pillar of earnings.
The company is absorbing rising raw material costs through price revisions and a shift toward higher value-added product mixes, thereby improving margins. In Q1 FY2026 (ending December 2026), this contributed a profit increase of +¥157 million from product mix and price revision effects and +¥200 million from manufacturing cost reductions. The full-year operating profit forecast for the alcoholic beverages business in FY2026 (ending December 2026) is conservatively set at ¥2,300 million (down 10.0% year on year).
The company plans to increase its annual dividend forecast for FY2026 (ending December 2026) from ¥11 in the previous period to ¥12, and on May 12, 2026, resolved to conduct a share buyback with an upper limit of 1.5 million shares and a maximum acquisition value of ¥795 million, aiming to enhance shareholder returns and improve capital efficiency.
Last updated: July 17, 2026